IGF1R and ovarian carcinoma: Increased expression and activation of various members of HER family receptors are observed after treatment with IGF-IR/InsR inhibitor in ovarian cancer cells, suggesting that up-regulation of HER pathway is sufficient to mediate resistance to IGF-IR-targeted therapy [124, 125].